About Topelia

Topelia Aust Limited (ABN 36 652 771 670) is an innovative, public unlisted biotechnology company dedicated to developing and commercialising its proprietary Antiviral Triple Therapy (ATT), known as TPL101. After successfully commercialising a Triple Therapy for Helicobacter pylori, Topelia’s leadership is now focused on leveraging their expertise to develop TPL101, initially targeted at treating COVID-19 infections.

TPL101 is designed to enhance current COVID-19 strategies, working alongside vaccines and authorised antiviral treatments. As the world continues to face persistent COVID-19 outbreaks, it’s essential to offer a broader range of safe antiviral therapies, particularly in light of increasing vaccine hesitancy and declining interest in current antiviral options.

TPL101 combines ivermectin and doxycycline, medications with long-standing safety profiles, and zinc in a proprietary fixed-dose combination. By using known, regulator-approved APIs, the development process for TPL101 promises to be faster, more cost-effective, and lower risk. Topelia is currently on track to conduct its Phase 3 trial and plans to seek TGA approval in CY2025. 

Given its mechanism of action, which targets proteins conserved across various viruses, Topelia plans to investigate TPL101’s effectiveness against other respiratory viral infections, including Avian influenza and diseases caused by the Flaviviridae family (such as Dengue, Zika, and Yellow Fever).